Yervoy

Active Ingredient(s): Ipilimumab
FDA Approved: * March 25, 2011
Pharm Company: * BRISTOL MYERS SQUIBB
Category: Cancer

Ipilimumab, sold under the brand name Yervoy, is a monoclonal antibody medication that works to activate the immune system by targeting CTLA-4, a protein receptor that downregulates the immune system. Cytotoxic T lymphocytes (CTLs) can recognize and destroy cancer cells. However, an inhibitory mechanism interrupts this destruction.[6] Ipilimumab turns off this inhibitory mechanism and boosts the body's immune response against cancer cells.[6][7]... [wikipedia]

* May have multiple approval dates, manufacturers, or labelers.
1 Discussion

Dosage List

Yervoy 5 mg/ml Intravenous Injection

NDC: 0003-2327

Labeler:

E.r. Squibb & Sons, L.L.C.

Yervoy 5 mg/ml Intravenous Injection

NDC: 0003-2328

Labeler:

E.r. Squibb & Sons, L.L.C.